Literature DB >> 26253632

Biarylmethoxy 2-nitroimidazooxazine antituberculosis agents: Effects of proximal ring substitution and linker reversal on metabolism and efficacy.

Andrew M Thompson1, Adrian Blaser2, Brian D Palmer2, Scott G Franzblau3, Baojie Wan3, Yuehong Wang3, Zhenkun Ma4, William A Denny2.   

Abstract

Certain biaryl analogues of antitubercular drug PA-824 displayed enhanced in vivo efficacies yet retained some susceptibility towards oxidative metabolism; therefore, two new strategies were explored to address this. Ortho-substitution of the proximal aryl ring with larger electron-withdrawing substituents maintained or improved compound stability but reduced aerobic potency; however, fluoro and cyano were well tolerated. In vivo, only 2'- or 3'-fluoro mono-substitution preserved high efficacy against acute infection, although one example was twofold more effective than delamanid against chronic infection. Reversal of the 6-oxymethylene linkage also permitted high potency and improved stability towards human liver microsomes, albeit, in vivo results were inferior. These novel findings provide further insight into the preferred structural features for lead candidates in this important drug class.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Delamanid; In vivo efficacy; Metabolism; Nitroimidazole; PA-824; Tuberculosis

Mesh:

Substances:

Year:  2015        PMID: 26253632     DOI: 10.1016/j.bmcl.2015.07.084

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

1.  Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid.

Authors:  Andrew M Thompson; Muriel Bonnet; Ho H Lee; Scott G Franzblau; Baojie Wan; George S Wong; Christopher B Cooper; William A Denny
Journal:  ACS Med Chem Lett       Date:  2017-11-13       Impact factor: 4.345

2.  Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.

Authors:  Andrew M Thompson; Patrick D O'Connor; Andrew J Marshall; Adrian Blaser; Vanessa Yardley; Louis Maes; Suman Gupta; Delphine Launay; Stephanie Braillard; Eric Chatelain; Baojie Wan; Scott G Franzblau; Zhenkun Ma; Christopher B Cooper; William A Denny
Journal:  J Med Chem       Date:  2018-03-06       Impact factor: 7.446

3.  7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.

Authors:  Andrew M Thompson; Patrick D O'Connor; Andrew J Marshall; Vanessa Yardley; Louis Maes; Suman Gupta; Delphine Launay; Stephanie Braillard; Eric Chatelain; Scott G Franzblau; Baojie Wan; Yuehong Wang; Zhenkun Ma; Christopher B Cooper; William A Denny
Journal:  J Med Chem       Date:  2017-05-11       Impact factor: 7.446

4.  Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.

Authors:  Andrew M Thompson; Andrew J Marshall; Louis Maes; Nigel Yarlett; Cyrus J Bacchi; Eric Gaukel; Stephen A Wring; Delphine Launay; Stephanie Braillard; Eric Chatelain; Charles E Mowbray; William A Denny
Journal:  Bioorg Med Chem Lett       Date:  2017-10-27       Impact factor: 2.823

Review 5.  Recent Progress in the Discovery and Development of 2-Nitroimidazooxazines and 6-Nitroimidazooxazoles to Treat Tuberculosis and Neglected Tropical Diseases.

Authors:  Hollis D Showalter
Journal:  Molecules       Date:  2020-09-10       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.